A Case Report of a Successful Allergen Immunotherapy with Candida Albicans in Patient with Sever Atopic Dermatitis Sensitive to Candida Albicans

Document Type: Case Report


1 Allergy Research Center, Mashhad University of Medical Sciences,Mashhad,Iran.

2 Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences,Mashhad,Iran.

3 Cutaneous Leishmaniasis Research Centr, Mashhad University of Medical Sciences,Mashhad,Iran.


Introduction: Atopic dermatitis (AD) is an inflammatory, chronic, relapsing, itchy skin disease with an immunologic basis. This disease is associated with itchy skin lesions (pruritus), dry skin (xerosis) and plaques of eczema. The role of aeroallergens, such as house dust mite (HDM) and food allergens has been proven to exacerbate skin eczema lesions. Alongside drugs such as corticosteroids, topical emollients, antihistamines, tacrolimus, and immune suppressants, phototherapy and subcutaneous immunotherapy (SCIT) also done. SCIT is mostly using for sensitization to mite allergens.
Case Presentation: We present a 30 y/o Iranian woman with severe atopic dermatitis and sensitization to Candida allergens. We initiated SCIT with candida allergen and the patient had obvious improvements in her signs and symptoms 3 months after starting SCIT.
Conclusion: Although subcutaneous immunotherapy was only approved for mite sensitization in atopic dermatitis, it should be considered in other aeroallergen sensitizations.


1- Pajno GB, Peroni  DG, Barberio G, Pi etrobel l i  A,Boner AL. Predictive features  for persistence of atopic dermatitis in children. Pediatr Allergy Immunol. 2003; 14(4):292-5.
2- Stensen L, Thomsen SF, Backer V. Change in preval ence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc. 2008; 29(4):392-6.
3- Werfel  T, Breuer K, Rueff F, Przybi l l a B, Worm M, Grewe M, et al . Useful ness of specific immunotherapy i n pati ents wi th atopic dermati ti s and allergic sensitization to house dust mi tes: a mul ti -centre,randomized, dose–response study. Allergy.2006; 61(2):202-5. 
4- Farid R, Ahanchian H, Jabbari F, Moghiman T.Effect of a new synbi oti c mi xture on atopic dermatitis in children: a randomized-controlled trial. Iran J Pediatr. 2011; 21(2):225-30.  
5- Bousquet J, Van Cauwenberge P, Khaltaev N;Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5):S147-334.
6- Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does al l ergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006; 118(6):1292-8.
7- Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopi c dermati tis in children and adul ts: European Academy of Allergology and Clinical Immunology/American Academy of Al l ergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol. 2006; 118(1):152-69.
8- Boguniewicz M, Schmid-Grendel meier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006; 118(1):40-3. 
9- Till SJ, Franci s JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004; 113(6):1025-34.
10- Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy Asthma Immunol Res. 2015; 7(3):221-9.  
11- Arzumanyan VG, Magarshak OO, Semenov BF. Yeast fungi in patients with allergic diseases: species variety and sensitivity to antifungal drugs. Bull Exp Biol Med. 2000; 129(6):601-4. 
12- Samaranayake YH, Samaranayake LP. Experimental oral candidias is in animal models. Clin Microbiol Rev. 2001; 14(2):398-429.